Organoprotective effects of serelaxin in patients with severe decompensated heart failure
Serelaxin (recombinant molecule of the human relaxin-2) is an innovative drug for the treatment of acute heart failure. Preclinical and clinical studies demonstrated the ability of serelaxin to relieve the symptoms of heart failure, provide a significant reduction in congestion and have a protective...
Main Authors: | Z. D. Kobalava, S. V. Villevalde, A. E. Solov'jova, I. A. Merai |
---|---|
Format: | Article |
Language: | English |
Published: |
Stolichnaya Izdatelskaya Kompaniya
2016-09-01
|
Series: | Racionalʹnaâ Farmakoterapiâ v Kardiologii |
Subjects: | |
Online Access: | https://www.rpcardio.com/jour/article/view/1305 |
Similar Items
-
NEW PROSPECTS IN PHARMACOLOGICAL TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE. EXPERIENCE WITH SERELAXIN. A CLINICAL CASE
by: S. D. Mayanskaya
Published: (2017-12-01) -
CLINICAL AND ECONOMICAL ASPECTS OF NOVEL APPROACHES TO THE TREATMENT OF CHRONIC HEART FAILURE DECOMPENSATION
by: S. K. Zyryanov, et al.
Published: (2015-03-01) -
Serelaxin: insights into its haemodynamic, biochemical, and clinical effects in acute heart failure
by: Hernández, Adrian V.
Published: (2014) -
A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)
by: Fiona J. Gifford, et al.
Published: (2020-03-01) -
Organoprotection and quality of life in elderly hypertensive patients receiving indapamide treatment
by: M. E. Statsenko, et al.
Published: (2006-08-01)